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Antibacterial factor 2 (ABF-2) is a 67-residue antimicrobial peptide derived from the nematode Caenorhabditis
elegans. Although it has been reported that ABF-2 exerts in vitro microbicidal activity against a range of bacteria
and fungi, the structure of ABF-2 has not yet been solved. To enable structural studies of ABF-2 by NMR
spectroscopy, a large amount of isotopically labeled ABF-2 is essential. However, the direct expression of ABF-2 in
Escherichia coli is difficult to achieve due to its instability. Therefore, we applied a coexpression method to the
production of ABF-2 in order to enhance the inclusion body formation of ABF-2. The inclusion body formation of
ABF-2 was vastly enhanced by coexpression of aggregation-prone proteins (partner proteins). By using this method,
we succeeded in obtaining milligram quantities of active, correctly folded ABF-2. In addition, 15 N-labeled ABF-2 and
a well-dispersed heteronuclear single quantum coherence (HSQC) spectrum were also obtained successfully.
Moreover, the effect of the charge of the partner protein on the inclusion body formation of ABF-2 in this method
was investigated by using four structurally homologous proteins. We concluded that a partner protein of opposite
charge enhanced the formation of an inclusion body of the target peptide efficiently.
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Antimicrobial peptides play an important role in innate
immunity as a part of the host defense response (Ganz
2003; Radek and Gallo 2007). Antimicrobial peptides are
thought to kill bacteria by breaking their cell mem-
branes, although the exact mechanisms are still unclear
(Sato and Feix 2006; Mani et al. 2005). To date, numer-
ous antimicrobial peptides have been identified in a wide
range of organisms, such as mammals, insects, and
plants (Zasloff 2002).
The nematode Caenorhabditis elegans has been suc-
cessfully used as a model species in many fields of bio-
logical research (Kaletta and Hengartner 2006; Walhout
et al. 2000). Due to its lack of an adaptive immune sys-
tem, this tiny worm relies solely on its innate immune* Correspondence: aizawa@mail.sci.hokudai.ac.jp
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in any medium, provided the original work is pdefense to cope with pathogen attacks. Therefore, the
worm is widely used in the study of host innate immun-
ity, and antibacterial molecules related to its innate
immunity have been identified (Schulenburg et al. 2004;
Roeder et al. 2010).
Antibacterial factor (ABF) is an antimicrobial peptide
identified in C. elegans (Kato et al. 2002). ABF was first
found by a computer-assisted search of a database using
the amino acid sequence of Ascaris suum antibacterial
factor (ASABF) (Zhang et al. 2000). Both ABF and
ASABF are thought to belong to a cysteine-stabilized α-
helix and β-sheet (CSαβ) superfamily, which contains a
single α-helix and a pair of anti-parallel β-sheets stabi-
lized by three or four disulfide bridges. Until now, six
kinds of ABF (ABF-1 ~ 6) have been identified from C.
elegans (Froy 2005). However, the antimicrobial activity
has been characterized for only one of these ABFs, ABF-2.
A previous study reported that ABF-2 has a broad anti-
microbial spectrum compared to that of other CSαβ-typeis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Sequences of primers used in this study
Name Primer sequencea
(from 5′ end to 3' end)
Restriction
site
Primers for ABF-2 gene F = GGAATTCCATATGGACATCG NdeІ
ACTTTAGTACTTGTGC
R = CCGCTCGAGTTATCCTCTCT XhoІ
TAATAAGAGCACCAAG
Primers for HLA gene F = GAATTCTCATGAAGCAATTC BspHІ
ACAAAATGTGAGCTG
R = CGGGATCCTTACAACTTCTC BamHІ
ACAAAGCCACTG
Primers for BLA gene F = GAATTCCCATGGAACAGTTA NcoІ
ACAAAATGTGAGGTG
R = CGGGATCCTTACAACTTCTC BamHІ
ACAGAGCCA
Primers for HLZ gene F = GAATTCTCATGAAGGTCTTT BspHІ
GAAAGGTGTGAGTTG
R = CGGGATCCTTACACTCCACA BamHІ
ACCTTGAACATAC
Primers for BLZ gene F = GAATTCTCATGAAGGTCTTT BspHІ
GAGAGATGTGAGC
R = CGGGATCCTTACAGGGTGCA BamHІ
ACCCTCAA
a. Restriction sites are underlined.
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C-terminal region of ABFs is longer and more widely di-
verse than that of other CSαβ-type antimicrobial peptides.
Moreover, ABFs differ from the “classical” CSαβ-type
antimicrobial peptides, such as drosomycin and plant
defensins, in terms of the spacing of half-cystine resi-
dues, cysteine pairings, and the organization of the pre-
cursor. Therefore, it is thought that the structural
properties of ABFs may contribute to their broad anti-
microbial spectrum. Although the CSαβ structure of
ASABF was solved by 1H-NMR (Aizawa et al., manu-
script in preparation), the structure of ABF-2 remains
unclear. Therefore, the structural analysis of ABF-2 will
provide new clues to clarify the structure-activity rela-
tionships of ABFs.
In general, the recombinant production of antimicro-
bial peptides has been difficult because of their activity,
although such production has used successfully in a
number of studies. In addition, ABF-2 contains four
intramolecular disulfide bridges, and thus it is difficult
to produce correctly folded and active ABF-2. There are
two major methods for producing recombinant peptides
that require the formation of disulfide bridges for proper
folding and function. One method uses the yeast secretory
expression system. Recombinant peptide expression in
yeast has many advantages, such as disulfide bridge forma-
tion and proper folding (Porro et al. 2005). The yeasts
Pichia pastoris and Saccharomyces cerevisiae are widely
used as expression hosts for recombinant peptides. How-
ever, a previous study reported that the expression level of
ABF-2 in P. pastoris was extremely low (100 μg/L) (Kato
et al. 2002). In addition, in the case of overexpression of
ASABF by using P. pastoris, it was reported that unfavor-
able degradation occurred in the C-terminus (Zhang et al.
2000). The other method is to refold the inclusion body
into peptides with native conformations (Singh and Panda
2005). In this study, we chose E. coli as an expression host
and tried to express ABF-2 as an inclusion body in E. coli.
Unfortunately, when ABF-2 was directly overexpressed, its
expression as an inclusion body in E. coli was low. In this
study, therefore, we applied a coexpression method for the
production of ABF-2 to enhance the inclusion body forma-
tion. In this method, the coexpression of an aggregation-
prone protein (partner protein) was expected to enhance
the inclusion body formation of the peptide of interest (tar-
get peptide), and to protect the target peptide from proteo-
lytic degradation by protease. Moreover, we evaluated the
effect of the charge of partner proteins on the inclusion
body formation of ABF-2 in this method by using four
structurally homologous proteins. As far as we know,
this is the first report to show experimentally that the
isoelectric point of the coexpressed partner protein is
an important factor for inclusion body formation of the
target peptide.Materials and methods
Materials
E. coli DH5α was used as a host strain for cloning and
for preparing template plasmids. E. coli BL21(DE3) was
used as an expression host. 15 N-labeled CHL medium
was purchased from Chlorella Industry.
Construction of a vector coexpressing ABF-2 and a
partner protein
The ABF-2 gene [GenBank: NM_058851] fragment was
amplified by PCR with a set of primers using a cDNA-
containing vector (Kato et al. 2002) as template (Table 1).
This product was ligated to the pCOLADuet1 vector
(Novagen) by using NdeІ-XhoІ sites (Figure 1), and the
resulting vector was designated pCOLA-ABF-2. In this
study, we selected four kinds of aggregation-prone proteins
(human α-lactalbumin (HLA) [GenBank: NM_002289],
bovine α-lactalbumin (BLA) [GenBank: NM_174378], hu-
man lysozyme (HLZ) [GenBank: NM_000239], and bovine
lysozyme (BLZ) [GenBank: NM_180999]) as partner pro-
teins. Each partner protein gene fragment was amplified by
PCR with a set of primers using the cDNA-containing vec-
tor (Aizawa et al. 1998; Masaki et al. 2000; Nonaka et al.
2009) as template (Table 1). The PCR-amplified partner
protein gene fragments (HLA, BLA, HLZ, and BLZ)





NcoI BamHI NdeI XhoI
Figure 1 Schematic representation of the expression vector.
pro, T7 promoter; SD, Shine-Dalgarno sequence; ter, T7 terminator.
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NcoІ-BamHІ sites. The gene fragments were included in
the vector name; for example the pCOLA-ABF-2 vector
containing the HLA gene was designated pCOLA-
[HLA]-ABF-2. The clone sequence was confirmed by
capillary sequencing.
Evaluating the effect of the partner protein on the ABF-2
expression level
E. coli BL21(DE3) cells were transformed with the
various expression constructs (pCOLA-[HLA]-ABF-2,
pCOLA-[BLA]-ABF-2, pCOLA-[HLZ]-ABF-2, pCOLA-
[BLZ]-ABF-2, and pCOLA-ABF-2). The transformed cells
were grown at 37°C in 5 mL of LB medium until the OD600
reached 1.0-1.2. The cells were induced by the addition of
1 mM isopropyl-β-D-thiogalactopyranoside (IPTG), culti-
vated for an additional 4 h, then harvested by centrifuga-
tion at 15,000 rpm for 5 min at 4°C. After the cells were
lysed using Bugbuster (Novagen), inclusion bodies were
isolated by centrifugation at 15,000 rpm for 5 min at
4°C and analyzed on Tricine-SDS PAGE. The intensity
of ABF-2 bands was quantified by densitometry.
Expression and purification of ABF-2
The E. coli strain BL21(DE3) harboring the pCOLA-
[BLA]-ABF-2 vector was cultured overnight at 37°C in
50 mL of LB medium containing 20 μg/mL kanamycin.
This preculture was inoculated in 1 L of medium (LB or
15 N-CHL) containing 20 μg/mL kanamycin. The culturewas grown at 37°C, and protein expression was induced
by the addition of 1 mM IPTG when the OD600 reached
1.0-1.2. At this point, for the production of 15 N-labeled
ABF-2, a 15 N-labeled algal amino acid mixture was added
to the CHL medium according to the protocol provided
by the supplier. After an additional 4 h of cultivation, cells
were harvested by centrifugation at 6,000 rpm for 10 min.
The cells were resuspended in lysis buffer (20 mM Tris–
HCl, 1 mM EDTA, pH 8.0) and disrupted by sonication.
Next, inclusion bodies composed mainly of BLA and
ABF-2 were isolated by centrifugation at 7,500 rpm for
30 min at 4°C. The inclusion bodies were washed twice
with lysis buffer containing 0.1% TritonX-100 and washed
once with lysis buffer (without TritonX-100).
The washed inclusion bodies were solubilized in sol-
ubilization buffer (8 M urea, 200 mM β-mercaptoethanol,
20 mM Tris–HCl, 3 mM EDTA, pH 8.0). After centrifu-
gation at 7,500 rpm at 4°C for 30 min, the clarified
supernatant was loaded onto a HiTrap SP HP cation-
exchange column (GE Healthcare) pre-equilibrated with
equilibration buffer (8 M urea, 20 mM Tris–HCl,
20 mM β-mercaptoethanol, 3 mM EDTA, pH 8.0). The
bound ABF-2 was eluted with a linear gradient of equili-
bration buffer with 0–600 mM NaCl. The fractions
containing ABF-2 were identified using Tricine-SDS
PAGE. These fractions were collected and dialyzed three
times against refolding buffer (20 mM Tris–HCl, 2 mM
reduced glutathione, 0.2 mM oxidized glutathione,
pH 8.0) for 12 h at 4°C. Correctly folded ABF-2 was puri-
fied by RP-HPLC on a Cosmosil 5C18-AR-300 column
(Nacalai Tesque). The elution was carried out with a linear
gradient of 25-45% acetonitrile with 0.1% trifluoroacetic
acid. The yield of ABF-2 was determined by measuring
the absorbance at 280 nm. The purified recombinant
ABF-2 was lyophilized and stored at −30°C.
Microbicidal assay
The antimicrobial activity of ABF-2 against S. aureus
ATCC6538P and E. coli K12 was tested by a colony-
forming unit assay. Bacteria were grown in tryptic soy
broth (TSB) and collected in the mid-log phase by
centrifugation. The bacteria were washed and diluted in
sterile water. Various concentrations of ABF-2 were in-
cubated with 1 × 107 bacteria in a final volume of 50 μL
at 37°C for 2 h. After incubation, 1,000-fold dilutions
were prepared and 100 μL of the diluted samples was
plated on a solid medium comprised of TSB. The plates
were incubated for 20 h at 37°C and then the colonies
were counted. The results indicated a 50% bactericidal
concentration (BC50).
Circular dichroism spectroscopy analysis
Circular dichroism (CD) spectra were measured in 1 mm
















































Figure 2 Effects of the charges of partner proteins on the
ABF-2 expression level. (a) Tricine-SDS-PAGE analysis of the
expression level of ABF-2. (b) The intensity data of the coexpression
method are expressed in relation to those for the direct expression
method. The graph represents the average intensities of three
independent experiments.
Table 2 Properties of antibacterial factors and partner
proteins used in this study
Name Mw pI GRAVY scorea
Antibacterial factor 2 (ABF-2) 6999.2 9.1 −0.072
Human α-lactalbumin (HLA) 14078.2 4.7 −0.255
Bovine α-lactalbumin (BLA) 14186.1 4.8 −0.453
Human lysozyme (HLZ) 14700.7 9.3 −0.485
Bovine lysozyme (BLZ) 14415.2 6.5 −0.395
a. GRAVY stands for grand average of hydropathy. The Positive GRAVY scores
indicate hydrophobic peptides, and negative scores indicate
hydrophilic peptides.
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tra were acquired over a wavelength range between
250 nm and 200 nm as an average of four spectra with a
50 nm/min scan speed and a step resolution of 0.1 nm at
25°C. ABF-2 samples (50 μM) were used in buffer (20 mM
Tris–HCl, pH 8.0). Buffer blanks were subtracted from all
spectra. All measurements were averaged and converted
to molar ellipticity.
NMR spectroscopy
15 N-labeled ABF-2 was dissolved in 20 mM phosphate
buffer (pH 5.7) comprising a 90% H2O/10% D2O mixture.
NMR experiments were performed on a JEOL ECA-600
spectrometer and a Bruker AVANCE ІІІ 800 spectrometer
with a TCI cryogenic probe. The 1H-15N HSQC spectrum
was collected at 20°C. The data were processed by using
NMRpipe/NMRdraw software (Delaglio et al. 1995).
Results
Construction and expression of coexpression plasmids
encoding ABF-2 and partner proteins
First, we tried to express ABF-2 as an inclusion body in
E. coli, but the expression level of ABF-2 was extremely
low (Figure 2). To enhance the inclusion body formation
of ABF-2, we decided to apply a coexpression method.
To construct a coexpression plasmid containing ABF-
2 and aggregation-prone partner protein genes, we uti-
lized the commercially available pCOLADuet1 vector
from Novagen. This vector has two RBS sites flanking
two multiple cloning sites, which are under the control
of their respective T7 promoters. In this study, partner
protein genes were subcloned into the first multiple
cloning site of the pCOLA vector, and the ABF-2 gene
was subcloned into the second multiple cloning site of
the pCOLA vector.
To evaluate the effect of a partner protein on the ABF-2
expression level, various partner proteins and ABF-2 were
coexpressed (Table 2). The expression of ABF-2 was mod-
erately increased in the case of the coexpression of ABF-2
and BLZ (Figure 2). The expression of ABF-2 as an inclu-
sion body was markedly increased by coexpression of HLA
or BLA. On the other hand, the expression level of ABF-2
was not affected, although HLZ was clearly overexpressed
as an inclusion body. Because the expression level of
ABF-2 was increased the most by coexpression of BLA,
we selected BLA as a partner protein for the large-scale
production of ABF-2.
Purification and refolding of ABF-2
ABF-2 was easily separated from BLA by using cation-
exchange chromatography under denaturing conditions,
because of the opposite charge (Figure 3). Unlike in fu-
sion protein systems, there was no need to remove the
fusion protein tag by enzymatic or chemical methods.After cation-exchange chromatography, we obtained
about 54 mg of crude ABF-2 without disulfide bonds
from 1 L of E. coli culture. Next, this crude ABF-2 was
refolded by dialysis. After the refolding and purification
procedure, we obtained 7.8 mg of correctly folded ABF-
2 from 1 L of culture.
Antimicrobial activity of recombinant ABF-2
The microbicidal activity of recombinant ABF-2 was ex-
amined (Table 3). The 50% microbicidal concentrations
were 0.01 and 0.1 μM for S. aureus and E. coli, respect-
ively. The Gram-positive bacterium (S. aureus) was 10-









Figure 3 Expression and purification of recombinant ABF-2.
Lane 1: Inclusion body after ultrasonication and centrifugation. Lane
2: Solubilized inclusion body. Lane 3: A flowthrough fraction that
was passed through cation-exchange chromatography. Lane 4:
Purified ABF-2 using cation-exchange chromatography. Lane 5:























Figure 4 Circular dichroism spectra of correctly folded (solid
line) and misfolded (dotted line) ABF-2.
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(E. coli). Neither S. aureus nor E. coli was sensitive to
the misfolded fraction (data not shown).Circular dichroism spectrum of ABF-2
Furthermore, to confirm that purified ABF-2 was folded
correctly, the CD spectra of ABF-2 were measured. The
spectra of misfolded ABF-2 revealed a random coil
structure (Figure 4). On the other hand, the CD spectra
of refolded ABF-2 showed a significant negative band in
the region between 208 and 220 nm. This indicates that
a secondary structure was formed in refolded ABF-2.1H-15N HSQC spectrum of 15 N-labeled ABF-2
The large amount of isotopically labeled ABF-2 enabled
the rapid and sensitive acquisition of NMR spectra. The
HSQC spectrum of 15 N-labeled ABF-2 is presented in
Figure 5. The number of peaks in the HSQC spectrum
of 15 N-labeled ABF-2 corresponded approximately to
the number of residues in ABF-2. The majority of the






Microbicidal activity was assessed as the 50% microbicidal
concentration (BC50).sharp, well-dispersed peaks indicate that purified ABF-2
was correctly folded.
Discussion
Because the correct disulfide arrangements of disulfide-
containing peptides are difficult to obtain, the yeast P.
pastris is widely used to express peptides containing
intramolecular disulfide bridges. The main advantage of
P. pastris as a host is that it is expected to secrete pep-
tides with correct disulfide bridges directly into culture
medium (Daly and Hearn 2005). Several CSαβ-type anti-
microbial peptides have been produced by using P.
pastris, and these were well characterized (Wang et al.
2008; Zhang et al. 2011; Wiens et al. 2011). However, aFigure 5 1H-15N HSQC spectrum of 0.7 mM 15 N-labeled ABF-2.
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host for large-scale production of ABF-2. Although the
antimicrobial spectrum of ABF-2 was investigated, struc-
tural and mutational studies of ABF-2 have not yet been
conducted because of the low yield of ABF-2 in P.
pastris (Kato et al. 2002). Therefore, it is very important
to develop an alternative expression method that en-
hances the expression level of ABF-2.
In this study, we selected E. coli as an expression host
and at first tried to express ABF-2 directly in E. coli as an
inclusion body. Unfortunately, the direct expression of
ABF-2 in E. coli was insufficient due to the instability of the
expressed ABF-2 itself in the cells (Figure 2). We specu-
lated that this low-level expression of ABF-2 was caused by
the degradation of expressed ABF-2 by proteases of E. coli.
Therefore, we considered that the prevention of ABF-2
degradation by proteases is essential to enhance the
expression level of ABF-2 as an inclusion body.
To prevent the degradation of target peptides, fusion
protein systems have been used in many studies. The at-
tachment of soluble proteins to target peptides has been
observed to prevent degradation and promote proper
folding (Xu et al. 2006). However, when an antimicrobial
peptide such as ABF-2 is expressed in a soluble form, it
may damage host cells by disrupting their cell membranes.
Moreover, in fusion protein systems, enzymatic or chem-
ical cleavage is inevitable to remove the fusion protein tag.
Enzymatic cleavage often degrades recombinant peptides,
because widely used proteases, such as enterokinase and
factor Xa, often show nonspecific cleavages at unexpected
sites. Furthermore, many peptides contain potential cleav-
age sites cleaved by chemicals. For instance, CNBr is
commonly used to cleave peptide bonds C-terminal to
methionine residues in proteins and peptides. However,
because ABF-2 contains methionine in its amino acid se-
quence, CNBr cannot be used to separate ABF-2 from the
fusion protein.
Expression of inclusion bodies may also be useful to
avoid proteolytic degradation of the target peptide. Walsh
et al. succeeded in expressing a large amount of amyloid
β-peptide (Aβ) directly as an inclusion body (Walsh et al.
2009). Because the Aβ peptide has a strong intrinsic pro-
pensity to aggregate, we considered that overexpression of
the Aβ peptide would readily lead to the formation of an
inclusion body in E. coli. This method is a very simple and
inexpensive way to produce a large amount of Aβ pep-
tides. However, it is generally difficult to control the inclu-
sion body formation in E. coli cells, especially in the case
of small and common peptides. As another way to pro-
duce fusion proteins, the utilization of insoluble protein
tags has also been reported (Park et al. 2009). This method
is expected to prevent both degradation and toxicity.
However, when an insoluble protein tag is used for the
fusion expression, it is difficult to employ enzymaticcleavage due to the insolubility of the fusion protein, and
chemical cleavage is usually necessary. This cleavage step
is thus one of the drawbacks of this method.
In some studies, the coexpression of an insoluble part-
ner protein has been reported to enhance the inclusion
body formation of the target peptide and protect it from
proteolytic degradation by protease. Saito et al. reported
that the expression level of somatomedin C was enhanced
in the case of coexpression of insulin-like growth factor І
(Saito et al. 1987). Jang et al. succeeded in producing a po-
tent antimicrobial peptide, buforin ІІb, by coexpression of
human gamma interferon (Jang et al. 2009). To obtain a
large amount of ABF-2, we decided to apply this method
to ABF-2 and examine the effects of aggregation-prone
partner proteins in detail.
In previous studies, translationally coupled two-cistron
plasmids were used to coexpress target peptides and
partner proteins (Saito et al. 1987; Jang et al. 2009). How-
ever, genetic manipulation was needed to construct the
translationally coupled two-cistron expression systems. In
the present study, we simply used the commercially
available pCOLADuet-1 vector to coexpress ABF-2 and
partner protein genes (Figure 1). Because this vector is
designed for the cloning and coexpression of two genes,
the construction of a coexpression plasmid is very easy.
Therefore, our method can be easily applied to many
proteins and peptides.
In this study, we chose four kinds of proteins as
aggregation-prone partners. Lysozyme and α-lactalbumin
appear to have evolved from a common ancestral protein,
as evidenced by the similarity of their amino acid se-
quences and three-dimensional structures as well as by
the high conservation of disulfide bridges (McKenzie and
White 1991). Some studies have clearly shown that these
four proteins each form a large amount of inclusion bod-
ies when overexpressed in E. coli (Svensson et al. 2000; Li
and Su 2002). Interestingly, the isoelectric points of these
proteins are different despite their sequential similarity.
Thus, we selected these proteins as good models of
aggregation-prone partners in order to evaluate the effect
of the charge of the partner protein on the expression
level of cationic ABF-2 (pI 9.1).
Coexpression of BLZ, whose isoelectric point is 6.5,
modestly enhanced the expression level of ABF-2. In
contrast, ABF-2 was produced effectively as an inclusion
body in the case of coexpression with an anionic partner
protein (HLA or BLA). Coexpression of HLZ, whose iso-
electric point is high, yielded no change in the expres-
sion level of ABF-2. Although it has been conjectured
that the charge of both target and partner proteins influ-
ences inclusion body formation, the effect of the charge
of the partner protein on the expression level of the tar-
get peptide has not been elucidated in detail. In this
study, we experimentally showed that the charge of the
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inclusion body formation of the target peptide. Interest-
ingly, although HLA and BLA have almost the same iso-
electric points and molecular weights, the expression
level of ABF-2 was enhanced more by coexpression of
BLA than by that of HLA. Because not only electrostatic
but also hydrophobic interactions are thought to be crit-
ical factors for inclusion body formation (Murby et al.
1995), we compared their GRAVY scores, which express
the total hydrophobicity of a protein. However, we could
not find a correlation between the expression level of
ABF-2 and the GRAVY scores of the partner proteins.
There may be unknown factors that affect inclusion
body formation.
It has been reported that the presence of impurities in
an inclusion body, such as nucleic acids and non-
plasmid-encoded proteins, affects the final refolding
yield of the target (Maachupalli-Reddy et al. 1997).
These impurities can be removed by washing the body
using a low concentration of detergent. Therefore, in-
clusion body washing is very important to enhance the
refolding yield of the target. However, in this study we
observed that the inclusion body composed of ABF-2
without partner proteins was gradually solubilized dur-
ing the washing process (data not shown). Because of
this unfavorable solubilization of the body, ABF-2 was
lost during the washing process and we could not obtain
even crude ABF-2 in the experiment using expression
without partner proteins. On the other hand, the inclu-
sion body composed of ABF-2 and the partner protein
showed almost no solubilization during the washing
process, suggesting that a robust inclusion body was
formed via coexpression of the peptide and a partner pro-
tein. From these results, it can be said that coexpression
of an aggregation-prone protein is effective not only to
enhance the expression level of a target peptide as an in-
clusion body but also to prevent the unfavorable loss of an
inclusion body during washing.
Because the charge of ABF-2 is opposite that of BLA,
we succeeded in separating ABF-2 from BLA efficiently
by a simple one-step cation-exchange chromatography
without enzymatic or chemical cleavage (Figure 3). After
cation-exchange chromatography, we succeeded in ob-
taining 54 mg of crude ABF-2 without disulfide bridges
from 1 L of culture. Although crude ABF-2 was refolded
by a very simple standard dialysis refolding protocol, we
obtained as much as 7.8 mg of correctly folded ABF-2.
Because refolding additives, such as arginine, have been
used to suppress the aggregation of proteins during
refolding in many studies (Arakawa et al. 2007), opti-
mization of the refolding protocol may enhance the
refolding yield of ABF-2.
To confirm that refolded ABF-2 was correctly folded
and active, purified ABF-2 was evaluated by a colony-forming unit assay as well as by CD and NMR spectros-
copy (Table 3, Figures 4, 5). We confirmed that purified
ABF-2 was active against both S. aureus and E. coli.
Moreover, S. aureus is more sensitive than E. coli. These
results were identical to the findings reported previously
(Kato et al. 2002). Quantitative analysis of the CD spec-
tra of purified ABF-2 indicated a secondary structural
content that included 28% α-helix and 17% β-sheet. This
result was in agreement with the categorization of ABF-2
as a CSαβ-type antimicrobial peptide. Moreover, the
HSQC spectrum of 15 N-labeled ABF-2 is sharp and well
dispersed. From these data, we concluded that purified
ABF-2 was correctly folded. This sample will enable us to
analyze the structure and molecular mechanism of ABF-2
by using NMR in future studies.
It is known that the long C-terminal regions of ABFs
are divergent and vary in length (Froy 2005). Therefore,
the difference in the C-terminal region of ABFs is thought
to affect their antimicrobial spectrum. We believe that the
method described in this work could be applied not only
to ABF-2 but also to other ABFs. In future studies, we
plan to use this technique to elucidate the effects of the
differences in the C-terminal regions of ABFs on their
antimicrobial spectra.
Here, we demonstrated that ABF-2 could be expressed
as an inclusion body in large quantities by coexpression
of an aggregation-prone protein. Moreover, the expression
level of ABF-2 was greatly enhanced by coexpression of
anionic partner proteins. After the refolding and purifica-
tion processes, we obtained milligram quantities of cor-
rectly folded ABF-2. Finally, this expression method
allowed stable isotopic labeling of recombinant ABF-2,
which is required for structural studies using multidimen-
sional heteronuclear NMR spectroscopy.
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